Recurrent myocardial infarction secondary to Prinzmetal’s variant angina

Dale Murdoch1,2, MBBS, FRACP, Priyanka Dhillon1, MBBS, Selvanayagam Niranjan1,3, FRACP

ABSTRACT Prinzmetal’s variant angina describes chest pain secondary to reversible coronary artery vasospasm in the context of both diseased and non-diseased coronary arteries. Symptoms typically occur when the patient is at rest and are associated with transient ST-segment elevation. Acute episodes respond to glyceryl trinitrate, but myocardial infarction and other potentially fatal complications can occur, and long-term management can be challenging. Although it is not well understood, the underlying mechanism appears to involve a combination of endothelial damage and vasoactive mediators. In this case, a 35-year-old woman with myocardial infarction secondary to coronary artery vasospasm experienced recurrent chest pain. Coronary angiography revealed severe focal stenosis in the mid left anterior descending artery, which completely resolved after administration of intracoronary glyceryl trinitrate. The patient was discharged on nitrates and calcium channel blockers. The patient re-presented with another myocardial infarction, requiring up-titration of medical therapy.

Keywords: coronary artery spasm, myocardial infarction, Prinzmetal’s variant angina, vasospastic angina

INTRODUCTION Prinzmetal’s variant angina (PVA) is an infrequent syndrome in which myocardial ischaemia is heralded by chest pain when a person is at rest, typically during early morning, and transient ST-segment elevation occurs due to reversible coronary artery vasospasm.1-4 This phenomenon, which is relieved by glyceryl trinitrate (GTN), can occur in diseased and non-diseased coronary arteries.1,2 In 1959, Dr Myron Prinzmetal hypothesised that variant angina was the result of vasospasm at the site of atherosclerotic lesions.1 Since then, coronary angiography has demonstrated that myocardial ischaemia due to coronary vasospasm can occur in the context of normal coronary arteries without macroscopic evidence of atherosclerosis or occlusion.3-6 However, accurate clinical, biochemical and electrocardiograph PVA diagnoses during patient presentation remain elusive, as the syndrome can mimic a number of pathologies, including ischaemic heart disease secondary to plaque rupture (type I acute myocardial infarction), takotsubo cardiomyopathy, pericarditis and pulmonary embolism.3,5 The problem of delayed diagnosis is often compounded by the transient nature of PVA. Although rare, PVA is associated with myocardial infarction, ventricular arrhythmias and death.6,7 The case presented herein demonstrates the difficulty in diagnosis and clinical management of PVA.

CASE REPORT A 35-year-old woman woke from sleep with central ‘squeezing’ chest pain that radiated to her back and was associated with left-arm paraesthesia. The pain was not pleuritic in character. The patient was dyspnoeic and experienced palpitations and nausea, and vomited once. She reported two episodes of chest pain that were ten minutes apart and of approximately ten minutes’ duration. The patient had been mildly unwell with an upper respiratory tract infection for seven days prior to this. She did not, however, have any infectious symptoms at presentation. Upon admission, she experienced another episode of chest pain in the emergency department, which resolved with GTN and intravenous morphine.

The patient’s medical history revealed previous radiofrequency catheter ablation for supraventricular tachycardia in 2005. She did not have hypertension, dyslipidaemia or diabetes mellitus. She was an ex-smoker who had quit eight years prior to presentation. The family history was significant, as her father had died of an acute myocardial infarction at the age of 40. His autopsy report demonstrated advanced coronary artery atherosclerosis with acute myocardial infarction.

The patient was not on any regular medication. On examination, her vitals were stable (heart rate 60 bpm; blood pressure 115/70; saturating at 100% on 2 L of oxygen; respiratory rate 16 breaths per minute; temperature 37.4°C). Heart sounds were dual with no murmurs. Jugular venous pressure was not elevated and there was no peripheral oedema. Chest sounds were normal on auscultation and an abdominal examination was unremarkable.

Initial electrocardiography (ECG) revealed no ischaemic changes in sinus rhythm (Fig. 1a) and cardiac troponin I (cTnI) level that was not elevated at 0.02 μg/L (reference range < 0.04 μg/L). Electrolytes, full blood count and lipids were normal. The patient was admitted to the coronary care unit where her ongoing anginal chest pain required escalation of therapy. Serial ECGs demonstrated anterior ST-segment elevation during chest pain and subsequently deep, symmetrical T-wave inversion in leads V1–3 (Fig. 1b & c). A repeat test after eight hours showed that the patient’s cTnI level was elevated at 0.3 ng/L (reference range < 0.04 ng/L).

Initial coronary angiography in the left anterior oblique cranial projection showed a tapering 90% mid left anterior descending (LAD) stenosis just after the first diagonal artery. Intracoronary GTN was administered and the focal LAD stenosis disappeared completely (Fig. 2). A left ventriculogram showed a focal area of...
Fig. 1 Serial ECGs show (a) an initially normal ECG; (b) anterior ST-segment elevation recorded at the time of pain; and (c) subsequent deep, symmetrical T-wave inversion indicating myocardial ischaemia/infarction.

Fig. 2 Diagnostic coronary angiograms show (a) severe stenosis in the mid left anterior descending artery (arrow) on the initial injection; and (b) complete resolution of stenosis (arrow) after administration of 200 mcg of intracoronary glyceryl trinitrate.
anterolateral hypokinesia. A diagnosis of coronary artery spasm (PVA) with secondary acute myocardial infarction was made.

Cardiac magnetic resonance imaging demonstrated that left-ventricular and right-ventricular size and function was normal with no valvular abnormality. There was no left-ventricular wall oedema to suggest myocarditis and no evidence of significant myocardial scarring. The patient was treated with diltiazem sustained-release (SR) 240 mg daily, isosorbide mononitrate SR 60 mg daily and GTN spray as required. She was discharged from hospital with follow-up arrangements in place.

Five months after her initial presentation, the patient presented with four distinct episodes of central crushing pain in the chest that radiated to the left arm. The pain was associated with vomiting and diaphoresis, and was not relieved by GTN. Once again, ECGs demonstrated T-wave inversion in V1–3. A repeat test showed that cTnI level was elevated at 0.4 ng/L. The patient continued to experience chest pain while on the ward, and telemetry with ST-segment monitoring showed transient ST-segment elevation (Fig. 3). Her dose of isosorbide mononitrate SR was increased to 90 mg daily and nicorandil of 10 mg daily was added. Computed tomography coronary angiography that was performed after the administration of GTN demonstrated no coronary artery occlusion or calcification. The patient responded well to the adjustments in her medication and her symptoms were under control at one-year follow-up.

**DISCUSSION**

PVA is recognised as chest pain not precipitated by physical exertion and is associated with ST-segment elevation.\(^1\)–\(^4\) It is an important functional cardiac disorder associated with syncope, high-degree atrioventricular block, life-threatening arrhythmias, acute myocardial infarction and cardiac arrest.\(^2\)–\(^7\) Typically, chest pain secondary to PVA occurs in the early hours of the morning and responds well to GTN.\(^2\)–\(^7\) The symptoms are the result of vasospasm in normal or atherosclerotic cardiac vessels. Approximately 30% of patients who undergo coronary angiography in suspected acute coronary syndrome have no culprit lesion or have disease-free coronary arteries,\(^3\) and while some of these patients will have PVA, the exact proportion is unknown. A diagnosis can be confidently made by recording ST-segment elevation at the time of chest pain, but capturing these events can be difficult. Therefore, the use of telemetry or Holter monitoring with ST-segment monitoring is recommended. Provocation testing using intracoronary acetylcholine is safe and effective in demonstrating coronary artery vasospasm.\(^3\)

Although the exact aetiology of coronary vasospasm remains unclear, several mechanisms have been hypothesised.\(^5\) A combination of arterial wall dysfunction and vasoactive substances are thought to be involved. Primarily endothelial damage exposes arterial media to vasoconstrictors such as catecholamines, thromboxane A2, serotonin, endothelin and histamine.\(^5\)–\(^8\) Reports also suggest that an imbalance in local vasodilators such as prostacyclin and nitric oxide increases the hyperreactivity of cardiac arteries.\(^2\) In addition, endothelial nitric oxide synthase T-786C mutation has been associated with increased coronary artery basal tone due to a reduction in nitric oxide production.\(^10\) This, in turn, increases vessel susceptibility to vasoconstrictors such as acetylcholine and predisposition to coronary artery vasospasm.\(^10\)–\(^11\)

There appears to be a higher incidence of PVA in Asian countries as opposed to Caucasian populations.\(^2\)–\(^4\)–\(^12\) Miwa et al demonstrated a positive result in 93% of Japanese patients who underwent provocation testing,\(^13\) while a prevalence of 74% was found in a Taiwanese population.\(^14\) The CASPAR (coronary artery spasm in patients with acute coronary syndrome) study conducted in a Caucasian study group, in comparison, had a prevalence of coronary spasm of 49%.\(^3\) The disparity may be due to more diffuse involvement of coronary arteries, hyperreactivity and increased basal tone in the Japanese population.\(^15\)

Current treatment involves the use of calcium channel blockers, nitrates, nicorandil and fasudil. Dose titration and addition of other medications are often required. Long-acting calcium channel blockers have been shown to decrease the number of anginal attacks and are considered the mainstay of treatment.\(^4\)–\(^13\) For this reason, they are used routinely in the treatment of hypertension in Japan. In addition to medical management, smoking cessation correlates with a reduction in symptoms.
In conclusion, PVA remains a difficult diagnosis and management dilemma, and strong clinical suspicion and careful history-taking are paramount. Although the lack of diseased coronary vessels mitigates the risk of myocardial infarction to some extent, myocardial infarction is nevertheless a very real possibility, as was demonstrated in this case, and thus should not be underestimated. Patient risk factors and prognostic factors do not fundamentally allow for differentiation between acute coronary syndrome due to atherosclerotic disease and that which occurs in normal arteries. Although several attempts have been made, more research is required into management guidelines for PVA.

**REFERENCES**


Table I. The Japanese Coronary Spasm Association clinical risk score for patients with vasospastic angina.(12)

<table>
<thead>
<tr>
<th>Predictive factor</th>
<th>Score*</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of OHCA</td>
<td>4</td>
</tr>
<tr>
<td>Smoking</td>
<td>2</td>
</tr>
<tr>
<td>Angina at rest alone</td>
<td>2</td>
</tr>
<tr>
<td>Significant organic stenosis</td>
<td>2</td>
</tr>
<tr>
<td>Multivessel spasm</td>
<td>2</td>
</tr>
<tr>
<td>ST elevation</td>
<td>1</td>
</tr>
<tr>
<td>Beta-blocker use</td>
<td>1</td>
</tr>
</tbody>
</table>

*Low risk 0-2, intermediate risk 3-5, high risk ≥ 6, out of a possible range of 0-14. OHCA: out-of-hospital cardiac arrest.